IL122120A - Recombinant mva virus containing a foreign gene inserted in a naturally occuring deletion within the genome - Google Patents

Recombinant mva virus containing a foreign gene inserted in a naturally occuring deletion within the genome

Info

Publication number
IL122120A
IL122120A IL12212096A IL12212096A IL122120A IL 122120 A IL122120 A IL 122120A IL 12212096 A IL12212096 A IL 12212096A IL 12212096 A IL12212096 A IL 12212096A IL 122120 A IL122120 A IL 122120A
Authority
IL
Israel
Prior art keywords
genome
recombinant mva
naturally occuring
foreign gene
virus containing
Prior art date
Application number
IL12212096A
Other languages
English (en)
Other versions
IL122120A0 (en
Original Assignee
Gsf Forschungszentrum Umwelt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8097499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL122120(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gsf Forschungszentrum Umwelt filed Critical Gsf Forschungszentrum Umwelt
Publication of IL122120A0 publication Critical patent/IL122120A0/xx
Publication of IL122120A publication Critical patent/IL122120A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1247—DNA-directed RNA polymerase (2.7.7.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Manufacturing & Machinery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL12212096A 1995-07-04 1996-07-03 Recombinant mva virus containing a foreign gene inserted in a naturally occuring deletion within the genome IL122120A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK78295 1995-07-04
PCT/EP1996/002926 WO1997002355A1 (en) 1995-07-04 1996-07-03 Recombinant mva virus, and the use thereof

Publications (2)

Publication Number Publication Date
IL122120A0 IL122120A0 (en) 1998-04-05
IL122120A true IL122120A (en) 2005-07-25

Family

ID=8097499

Family Applications (5)

Application Number Title Priority Date Filing Date
IL12212096A IL122120A (en) 1995-07-04 1996-07-03 Recombinant mva virus containing a foreign gene inserted in a naturally occuring deletion within the genome
IL164318A IL164318A (en) 1995-07-04 2004-09-28 A vaccine that includes a recombinant Vaccinia ancara ankara that has undergone at least one foreign gene inserted into a naturally occurring missing site within the virus genome and its preparation
IL202448A IL202448A0 (en) 1995-07-04 2009-12-01 Vaccine comprising recombinant modified vaccine ankara virus and uses thereof
IL212933A IL212933A0 (en) 1995-07-04 2011-05-17 Eukaryotic cell comprising a recombinant modified vaccinia ankara (mva) virus
IL219528A IL219528A0 (en) 1995-07-04 2012-05-02 Vaccine comprising recombinant modified vaccine ankara virus and uses thereof

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL164318A IL164318A (en) 1995-07-04 2004-09-28 A vaccine that includes a recombinant Vaccinia ancara ankara that has undergone at least one foreign gene inserted into a naturally occurring missing site within the virus genome and its preparation
IL202448A IL202448A0 (en) 1995-07-04 2009-12-01 Vaccine comprising recombinant modified vaccine ankara virus and uses thereof
IL212933A IL212933A0 (en) 1995-07-04 2011-05-17 Eukaryotic cell comprising a recombinant modified vaccinia ankara (mva) virus
IL219528A IL219528A0 (en) 1995-07-04 2012-05-02 Vaccine comprising recombinant modified vaccine ankara virus and uses thereof

Country Status (26)

Country Link
US (6) US6440422B1 (de)
EP (3) EP0836648B1 (de)
JP (3) JP4312260B2 (de)
KR (1) KR19990028617A (de)
CN (3) CN1782071A (de)
AT (3) ATE304058T1 (de)
AU (1) AU721735B2 (de)
BR (1) BR9609303B8 (de)
CA (3) CA2225278C (de)
CZ (1) CZ292460B6 (de)
DE (3) DE69635172T2 (de)
DK (3) DK1312679T3 (de)
EE (3) EE04199B1 (de)
ES (3) ES2249648T3 (de)
HU (2) HU229261B1 (de)
IL (5) IL122120A (de)
MX (1) MX9800025A (de)
NO (1) NO322476B1 (de)
NZ (1) NZ313597A (de)
PL (1) PL186857B1 (de)
PT (1) PT836648E (de)
RU (1) RU2198217C2 (de)
SI (3) SI1312679T1 (de)
TW (2) TWI245075B (de)
UA (3) UA68327C2 (de)
WO (1) WO1997002355A1 (de)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US7118754B1 (en) * 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
EP0951555A2 (de) * 1996-09-24 1999-10-27 Bavarian Nordic Research Institute A/S Rekombinantes mva-virus das dengue-virus antigene exprimiert und dessen verwendung in impfstoffen
MY119381A (en) * 1996-12-24 2005-05-31 Gsf Forschungszentrum Umwelt Recombinant mva virus, and the use thereof
US6969609B1 (en) * 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
FR2784997A1 (fr) * 1998-10-22 2000-04-28 Transgene Sa Materiel biologique pour la preparation de compositions pharmaceutiques destinees au traitement de mammiferes
US20040265324A1 (en) * 1999-03-23 2004-12-30 Cardosa Mary Jane Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
DE60040662D1 (de) * 1999-05-28 2008-12-11 Helmholtz Zentrum Muenchen Vektor zur integration von heterologen sequenzen in poxvirusgenomen
US20150231227A1 (en) * 2000-03-02 2015-08-20 Emory University Compositions and methods for generating an immune response
RU2280075C2 (ru) 2000-03-14 2006-07-20 Бавариан Нордик А/С Измененный штамм модифицированного вируса коровьей оспы ankara (mva)
RU2217162C2 (ru) * 2000-04-10 2003-11-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Вакцина против вирусных инфекций
DE10042598A1 (de) * 2000-08-30 2002-03-28 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
WO2002031168A2 (en) * 2000-10-10 2002-04-18 Genstar Therapeutics Minimal adenoviral vector and recombinant vaccines based thereon
CN101676389A (zh) 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7740863B2 (en) 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
DE10144664B4 (de) * 2001-09-11 2005-06-09 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon
AU2002356690B2 (en) 2001-12-04 2008-07-24 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
US7056723B2 (en) * 2001-12-20 2006-06-06 Bavarian Nordic A/S Method for the recovery and purification of poxviruses from infected cells
DK1420822T4 (en) † 2002-04-19 2017-10-09 Bavarian Nordic As Modified vaccinia virus Ankara for vaccination of newborns
PL218318B1 (pl) 2002-05-16 2014-11-28 Bavarian Nordic As Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych
CA2481783A1 (en) * 2002-05-16 2003-11-27 Bavarian Nordic A/S Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
AU2003264144C1 (en) 2002-09-05 2009-12-17 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
DE10249390A1 (de) * 2002-10-23 2004-05-13 Ruprecht-Karls-Universität Heidelberg Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria
AU2003293675B2 (en) 2002-11-25 2009-04-23 Bavarian Nordic A/S Recombinant poxvirus comprising at least two cowpox ATI promoters
DE602004015418D1 (de) * 2003-02-18 2008-09-11 Helmholtz Zentrum Muenchen Rekombinantes mva und verfahren zur erzeugung davon
EP1601333B1 (de) * 2003-02-20 2013-01-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Neue einführungsstellen in pocken-vektoren
US7731974B2 (en) * 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
AU2004223808B2 (en) 2003-03-27 2009-03-26 Ottawa Health Research Institute Mutant vesicular stomatitis viruses and use thereof
US7163685B2 (en) * 2003-04-16 2007-01-16 City Of Hope Human cytomegalovirus antigens expressed in MVA and methods of use
GB2402391A (en) * 2003-06-04 2004-12-08 Oxxon Pharmaccines Ltd Fowlpox recombinant genome
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
US20100189747A1 (en) * 2003-07-31 2010-07-29 Raymond Weinstein Compositions and methods for treating or preventing hiv infection
EP1518932A1 (de) 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Mutierte Form des Modifizierten Vaccinia Virus Ankara (MVA) sowie ihre Verwendung
DE602004009743T2 (de) * 2003-11-24 2008-08-28 Bavarian Nordic A/S Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
WO2005054451A1 (ja) 2003-12-05 2005-06-16 Hokkaido Technology Licensing Office Co., Ltd. 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター
EP1683870A1 (de) * 2005-01-24 2006-07-26 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Auf die Verwendung von MVA basierte Impfstoffe
US20090269365A1 (en) * 2005-04-20 2009-10-29 University Of Washington Immunogenic vaccinia peptides and methods of using same
EP2023954B1 (de) * 2006-05-19 2013-07-17 Sanofi Pasteur, Inc. Immunologische zusammensetzung
ES2611975T3 (es) * 2006-06-20 2017-05-11 Transgene S.A. Procedimiento para producir poxvirus y composiciones de poxvirus
US7972605B2 (en) * 2006-09-08 2011-07-05 Duke University Modified vaccinia ankara virus vaccine
CN102026645B (zh) 2006-09-15 2016-01-27 渥太华医院研究机构 溶瘤弹状病毒
EP2073837B1 (de) 2006-10-06 2014-06-25 Bavarian Nordic Inc. Rekombinanter modifizierter vaccinia ankara-virus zur kodierung eines her-2-antigens in kombination mit einem taxan zur verwendung in der krebsbehandlung
US20080241139A1 (en) * 2006-10-31 2008-10-02 Regents Of The University Of Colorado Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
US8557764B2 (en) * 2007-01-26 2013-10-15 The Regents Of The University Of Colorado, A Body Corporate Methods of modulating immune function
JP2010526528A (ja) 2007-05-03 2010-08-05 メディツィニーチェ ウニベルシタット インスブルック 補体因子ｈ由来ショートコンセンサスリピート−抗体構築物
US8003364B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
US8012738B2 (en) * 2007-05-14 2011-09-06 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
US8003363B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
US20100285050A1 (en) * 2007-10-05 2010-11-11 Isis Innovation Limited Compositions and Methods
BRPI0800485B8 (pt) * 2008-01-17 2021-05-25 Univ Minas Gerais vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose
EP2240573A4 (de) 2008-02-12 2011-08-31 Sanofi Pasteur Ltd Verfahren mit verwendung von ionenaustausch- und gelfiltrationschromatographie zur poxvirus-reinigung
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
WO2010127115A1 (en) 2009-04-30 2010-11-04 Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) Modified immunization vectors
BR112012002628B1 (pt) 2009-08-07 2021-09-08 Transgene Sa Composição imunogênica, molécula de ácido nucleico, vetor, partícula viral infecciosa, micro-organismo transgênico, composição, usos da composição imunogênica e kit de partes
EP2501405A4 (de) * 2009-11-20 2013-12-04 Inviragen Inc Zusammensetzung, verfahren und verwendungen für poxvirenelemente in impfstoffkonstrukten
US9005632B2 (en) 2009-11-20 2015-04-14 Takeda Vaccines, Inc. Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
GB201006405D0 (en) * 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
US20110262965A1 (en) * 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
US20140093556A1 (en) 2011-01-28 2014-04-03 Sanofi Pasteur Sa Immunological Compositions Against HIV
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
ES2813413T3 (es) * 2011-08-05 2021-03-23 Sillajen Biotherapeutics Inc Métodos y composiciones para la producción de virus vaccina
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
WO2013046034A2 (en) * 2011-09-26 2013-04-04 Theravectys Use of non-subtype b gag proteins for lentiviral packaging
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
EP2620446A1 (de) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogene zur HIV-Impfung
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
WO2014009438A2 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterial antigen vaccine
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
EP3587455A1 (de) 2012-10-23 2020-01-01 Emory University Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
US20140286981A1 (en) 2013-03-14 2014-09-25 Wisconsin Alumni Research Foundation Broadly reactive mosaic peptide for influenza vaccine
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US10765731B2 (en) 2014-01-09 2020-09-08 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
GB201412494D0 (en) * 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
HUE053585T2 (hu) 2014-09-26 2021-07-28 Beth Israel Deaconess Medical Ct Inc Eljárások és készítmények humán immundeficiencia vírus fertõzés elleni védõ immunválasz indukálására
US11701418B2 (en) 2015-01-12 2023-07-18 Geovax, Inc. Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
PL3390430T3 (pl) 2015-12-15 2020-03-31 Janssen Vaccines & Prevention B.V. Antygeny ludzkiego wirusa niedoboru odporności, wektory, kompozycje i sposoby ich zastosowania
CA3011014A1 (en) 2016-01-08 2017-07-13 Geovax, Inc. Compositions and methods for generating an immune response to a tumor associated antigen
WO2017136419A1 (en) 2016-02-03 2017-08-10 Geovax Inc. Compositions and methods for generating an immune response to a flavivirus
US10736962B2 (en) * 2016-02-25 2020-08-11 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
EP3452081A1 (de) 2016-05-04 2019-03-13 Transgene SA Kombinationstherapie mit cpg-tlr9-liganden
KR102389489B1 (ko) 2016-06-16 2022-04-22 얀센 백신스 앤드 프리벤션 비.브이. Hiv 백신 제형
US10307477B2 (en) 2016-09-02 2019-06-04 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
SG10202001956UA (en) 2016-09-15 2020-04-29 Janssen Vaccines & Prevention Bv Trimer stabilizing hiv envelope protein mutations
EP3522920A2 (de) 2016-10-10 2019-08-14 Transgene SA Immuntherapeutisches produkt und mdsc-modulator-kombinationstherapie
BR112019026126A2 (pt) 2017-06-15 2020-06-30 Janssen Vaccines & Prevention B.V. vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
JP7334124B2 (ja) 2017-06-21 2023-08-28 トランジェーヌ 個別化ワクチン
EP3655032A1 (de) 2017-07-19 2020-05-27 Janssen Vaccines & Prevention B.V. Trimerstabilisierende hiv-hüllproteinmutationen
US20190022212A1 (en) 2017-07-21 2019-01-24 Beth Israel Deaconess Medical Center, Inc. Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
US20190083620A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
JP7551496B2 (ja) 2017-10-31 2024-09-17 カリヴィル イムノセラピューティクス， インコーポレイテッド 全身送達のためのプラットフォーム腫瘍溶解性ベクター
JP7320601B2 (ja) 2018-09-11 2023-08-03 上▲海▼市公共▲衛▼生▲臨▼床中心 広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
TW202110476A (zh) 2019-05-22 2021-03-16 荷蘭商傑森疫苗防護公司 於接受抗反轉錄病毒治療之個體中誘發抗人類免疫缺乏病毒感染之免疫反應的方法
KR20220011685A (ko) 2019-05-22 2022-01-28 길리애드 사이언시즈, 인코포레이티드 Tlr7 조절 화합물과 hiv 백신의 조합
CN114901297A (zh) * 2019-10-16 2022-08-12 卡利威尔免疫治疗公司 用于原位产生逆转录病毒的生产者病毒
EP4058058A1 (de) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosierungsschema für impfstoffe
EP3842065A1 (de) 2019-12-23 2021-06-30 Transgene Verfahren zum entwurf eines rekombinanten pockenvirus für einen therapeutischen impfstoff
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP3928789A1 (de) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-basierter impfstoff gegen covid-19 exprimierende sars-cov-2-antigene
PE20231175A1 (es) 2020-11-19 2023-08-01 Kalivir Immunotherapeutics Inc Inmunoterapia oncolitica por remodelacion del microambiente tumoral
IL316712B2 (en) 2021-04-30 2025-12-01 Kalivir Immunotherapeutics Inc Oncolytic viruses for modified mhc expression
EP4108257A1 (de) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Impfstoff auf mva-basis gegen covid-19, der ein präfusionsstabilisiertes sars-cov-2-s-protein exprimiert
WO2022269003A1 (en) 2021-06-23 2022-12-29 Consejo Superior De Investigaciones Cientificas MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
US20230364227A1 (en) 2022-05-12 2023-11-16 Pellis Therapeutics, Inc. Poxvirus adjuvant for t-cell vaccination
EP4316514A1 (de) 2022-08-03 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) Vektoren auf mva-basis und ihre verwendung als impfstoff gegen sars-cov-2
AU2024241503A1 (en) 2023-03-17 2025-08-14 Albert-Ludwigs-Universität Freiburg Hbv antigen formulation for treating hepatitis b
WO2025172435A1 (en) 2024-02-13 2025-08-21 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Hbv antigen formulation for treating hepatitis b
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787901A (fr) 1971-09-11 1972-12-18 Freistaat Bayern Represente Pa Vaccin antivariolique
JPH0795954B2 (ja) 1982-11-30 1995-10-18 アメリカ合衆国 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
US5679511A (en) * 1986-10-06 1997-10-21 Donald Guthrie Foundation For Medical Research, Inc. CDNA clones for a regulatory protein in the melanin-production pathway
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5221610A (en) * 1988-05-26 1993-06-22 Institut Pasteur Diagnostic method and composition for early detection of HIV infection
CN1042564A (zh) * 1988-11-11 1990-05-30 中国科学院上海生物化学研究所 乙肝疫苗的制备方法及其制品
JPH03271233A (ja) * 1990-03-19 1991-12-03 Inst Pasteur ウイルスエンベロープ糖タンパク質及びその糖タンパク質の中和エピトープに対応するペプチドの間の相乗作用による、ウイルス性感染に対する防御の誘発
JPH07501052A (ja) * 1991-10-28 1995-02-02 インスティチュート・パスツール ウイルスエンベロープタンパク質と糖タンパク質の中和エピトープに相当するペプチドとの間の相乗作用によるウイルス感染に対する防御の誘発
ES2151544T3 (es) * 1992-12-22 2001-01-01 Ludwig Inst Cancer Res Metodos para la deteccion y el tratamiento de individuos con celulas anormales que expresan antigenos peptidos hla-a2/tirosinasa.
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
AU685521B2 (en) * 1993-10-19 1998-01-22 Ajinomoto Co., Inc. Peptide capable of inducing immune response against HIV and aids preventive or remedy containing the peptide
US5676950A (en) * 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals

Also Published As

Publication number Publication date
HUP9802217A2 (hu) 1999-01-28
BR9609303B8 (pt) 2014-05-06
ATE304057T1 (de) 2005-09-15
HU229261B1 (en) 2013-10-28
DK1312678T3 (da) 2005-12-19
EP1312678A1 (de) 2003-05-21
ES2249647T3 (es) 2006-04-01
JP2007244382A (ja) 2007-09-27
IL212933A0 (en) 2011-07-31
EE200300331A (et) 2003-10-15
DE69635173T2 (de) 2006-07-13
CN1554764A (zh) 2004-12-15
CA2225278C (en) 2009-01-27
EP1312678B1 (de) 2005-09-07
US6440422B1 (en) 2002-08-27
ES2199294T3 (es) 2004-02-16
DK0836648T3 (da) 2003-08-25
ATE239796T1 (de) 2003-05-15
TW200305646A (en) 2003-11-01
ATE304058T1 (de) 2005-09-15
SI1312678T1 (sl) 2006-02-28
PT836648E (pt) 2003-09-30
EP1312679B8 (de) 2005-11-23
SI0836648T1 (en) 2003-12-31
CZ292460B6 (cs) 2003-09-17
JP4764367B2 (ja) 2011-08-31
EP1312679A1 (de) 2003-05-21
ES2249648T3 (es) 2006-04-01
DE69628011D1 (de) 2003-06-12
UA75410C2 (en) 2006-04-17
BR9609303A (pt) 1999-05-25
IL164318A0 (en) 2005-12-18
US8153138B2 (en) 2012-04-10
JP4312260B2 (ja) 2009-08-12
US20100266630A1 (en) 2010-10-21
US20030035792A1 (en) 2003-02-20
TW575664B (en) 2004-02-11
BR9609303B1 (pt) 2014-04-08
HU224061B1 (hu) 2005-05-30
UA75411C2 (en) 2006-04-17
EE200300332A (et) 2003-10-15
EP0836648B1 (de) 2003-05-07
AU721735B2 (en) 2000-07-13
UA68327C2 (en) 2004-08-16
CN1782071A (zh) 2006-06-07
NZ313597A (en) 1999-01-28
RU2198217C2 (ru) 2003-02-10
US8197825B2 (en) 2012-06-12
DE69635172T2 (de) 2006-06-22
CN1189857A (zh) 1998-08-05
HK1068015A1 (en) 2005-04-22
HU0402350D0 (en) 2005-01-28
EP0836648A1 (de) 1998-04-22
NO980026D0 (no) 1998-01-02
CA2596274C (en) 2010-09-07
DK1312679T3 (da) 2006-01-09
CZ424197A3 (cs) 1998-03-18
IL122120A0 (en) 1998-04-05
EE05138B1 (et) 2009-02-16
TWI245075B (en) 2005-12-11
HUP9802217A3 (en) 1999-09-28
CA2608864A1 (en) 1997-01-23
US20100291139A1 (en) 2010-11-18
DE69628011T2 (de) 2004-03-18
HK1009830A1 (en) 1999-06-11
US20070071769A1 (en) 2007-03-29
JP4764366B2 (ja) 2011-08-31
CA2596274A1 (en) 1997-01-23
EE9700344A (et) 1998-06-15
JPH11509091A (ja) 1999-08-17
JP2007252374A (ja) 2007-10-04
IL202448A0 (en) 2011-07-31
WO1997002355A1 (en) 1997-01-23
SI1312679T1 (sl) 2006-02-28
MX9800025A (es) 1998-03-31
CA2225278A1 (en) 1997-01-23
US20070071770A1 (en) 2007-03-29
CN1154742C (zh) 2004-06-23
PL186857B1 (pl) 2004-03-31
IL219528A0 (en) 2012-06-28
IL164318A (en) 2013-08-29
KR19990028617A (ko) 1999-04-15
CN1554764B (zh) 2012-03-21
PL324347A1 (en) 1998-05-25
NO980026L (no) 1998-01-02
NO322476B1 (no) 2006-10-09
US7198934B2 (en) 2007-04-03
DE69635172D1 (de) 2005-10-13
CA2608864C (en) 2010-09-07
DE69635173D1 (de) 2005-10-13
EE04753B1 (et) 2006-12-15
AU6611096A (en) 1997-02-05
EP1312679B1 (de) 2005-09-07
EE04199B1 (et) 2003-12-15

Similar Documents

Publication Publication Date Title
NZ313597A (en) Recombinant mva virus, and the use thereof
EP0677114A4 (de) Rekombinanter schweinepocken-virus.
EP0757717A4 (de) Papillomavirus vakzine
FR2705361B1 (fr) Vecteurs viraux et utilisation en thérapie génique.
WO1995026411A3 (en) Composition and methods for creating syngeneic recombinant virus-producing cells
NZ333975A (en) Recombinant swinepox virus
FI973309A0 (fi) Menetelmä yhdistelmä-DNA-adenovirusgenomin valmistamiseksi
FR2702152B1 (fr) Virus recombinants et leur utilisation en thérapie génique.
HUP9802587A2 (hu) Glükózzal indukálható rekombináns virális vektor, ezt tartalmazó gyógyszerkészítmény és ezzel transzformált sejtek
MY134484A (en) Recombinant mva virus, and the use thereof
MY119381A (en) Recombinant mva virus, and the use thereof
MY157873A (en) Recombinant mva virus, and the use thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired